Pre-Thrombectomy Assessment and Thromboprophylaxis in Cancer Patients

Critical Preoperative Assessments

The American Society of Clinical Oncology recommends that patients undergoing thrombectomy should have a platelet count >50 × 10³/μL to minimize bleeding risk 1, 2
Active bleeding or high bleeding risk represents an absolute contraindication to pharmacologic thromboprophylaxis and must be carefully evaluated before any major surgical intervention 1, 3
The surgeon must assess the extent of planned dissection and adequacy of anticipated intraoperative hemostasis, as cancer surgery carries greater bleeding risk independent of prophylaxis type 4

The American Society of Clinical Oncology recommends that all patients undergoing major surgical intervention for malignant disease should receive pharmacologic thromboprophylaxis with either UFH or LMWH unless contraindicated 1, 3, 4
The presence of malignant disease doubles the risk for DVT, with fatal PE occurring in 1-5% without perioperative thromboprophylaxis 4, 5
VTE risk factors to document include: restricted mobility, obesity, previous VTE history, advanced age, higher stage of disease, and prolonged anesthesia duration 4, 5

Pharmacologic prophylaxis should commence preoperatively or as early as possible postoperatively 1, 3
Mechanical methods (compression stockings, intermittent pneumatic compression) should be added to pharmacologic prophylaxis but never used as monotherapy unless pharmacologic methods are contraindicated 1, 3
Combined pharmacologic and mechanical prophylaxis improves efficacy, especially in highest-risk patients 1, 3

Minimum 7-10 days of pharmacologic thromboprophylaxis is required for all major cancer surgery 1, 3, 4
Extended prophylaxis for up to 4 weeks postoperatively should be offered if the patient has high-risk features including: restricted mobility, obesity, history of VTE, major open or laparoscopic abdominal or pelvic surgery for cancer, and residual malignant disease after operation 1, 4, 6, 7
The evidence for extended prophylaxis is strong, with reduction in symptomatic DVT from 1.7% to 0.2% (number needed to treat = 66) 8